Immutep

Golfer devastated after just barely missing a putt
Biotech

Immutep's ph. 3 failure surprises analysts, sinks stock

Immutep and the Australian biotech’s investors have been caught off guard by the unexpected failure of its LAG-3 candidate in a phase 3 study.
James Waldron Mar 13, 2026 9:53am
Asia map globe

Dr. Reddy's pens $370M pact for rights to Immutep's LAG-3 agent

Dec 8, 2025 10:55am
Step closer race run

Immutep's LAG-3 agent posts 'impressive' survival data

May 5, 2025 10:37am
step up climb ladder sky hang on rung

Immutep regains pep as cancer subgroup data show path forward

Jul 12, 2024 9:35am
parachute sunset paragliding chutes

BMS CEO set to leave after 8-year run—Chutes & Ladders

Apr 28, 2023 9:30am
close-up of money

LAG-3-focused Immutep secures cash, plots new trial push

Jun 21, 2021 7:10am